Plasma ofCS‐modified CD44 predicts the survival of patients with lung cancer
Rattachement africain : cn, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Plasma levels of oncofetal chondroitin sulfate (ofCS)-modified CD44 have emerged as a promising biomarker for multi-cancer detection. Here, we explored its potential to predict the survival of patients with lung cancer. A prospective observational cohort was conducted involving 274 newly diagnosed patients with lung cancer at the Sun Yat-sen University Cancer Center from 2013 to 2015. The plasma levels of ofCS-modified CD44 were measured, and Cox regression analysis was performed to assess the association between plasma-modified CD44 levels and overall survival (OS) as well as other prognostic outcomes. Prognostic nomograms were constructed based on plasma ofCS-modified CD44 levels to predict survival outcomes for patients with lung cancer. Patients with high expression ofCS-modified CD44 exhibited significantly worse outcomes in terms of OS (HR = 1.61, 95%CI = 1.13-2.29, p = 0.009) and progression-free survival (PFS). These findings were consistent across various analyses. The concordance index of the prognostic nomogram for predicting OS in both the training set and validation set were 0.723 and 0.737, respectively. Additionally, time-dependent receiver operating characteristic (ROC) curves showed that the nomogram could serve as a useful tool for predicting OS in patients with lung cancer. Plasma ofCS-modified CD44 may serve as an independent prognosis marker for patients with lung cancer. Further validation of its predictive value could enhance prognostic assessment and guide personalized treatment strategies for patients with lung cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Plasma ofCS‐modified CD44 predicts the survival of patients with lung cancer
- Date Crossref
- 27/08/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fujian Medical University Department of Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Sun Yat-sen University State Key Laboratory of Oncology in South China pays non établi dans la noticeUniversité ou école supérieure
-
Sun Yat-sen University Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Fujian Provincial Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
National Institutes of Health pays non établi dans la noticeOrganisme public
-
National Institute of Allergy and Infectious Diseases pays non établi dans la noticeStructure de recherche
-
Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China State Key Laboratory of Oncology in South China pays non établi dans la noticeUniversité ou école supérieure
-
School of Public Health pays non établi dans la noticeUniversité ou école supérieure
-
Laboratory of Malaria and Vector Research pays non établi dans la noticeStructure de recherche
Department of Radiation Oncology — Fujian Medical University, State Key Laboratory of Oncology in South China — Sun Yat-sen University et Sun Yat-sen University Cancer Center, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.